NO20076475L - Enkeltdomene VHH antilegemer mot Van Willebrand faktor - Google Patents
Enkeltdomene VHH antilegemer mot Van Willebrand faktorInfo
- Publication number
- NO20076475L NO20076475L NO20076475A NO20076475A NO20076475L NO 20076475 L NO20076475 L NO 20076475L NO 20076475 A NO20076475 A NO 20076475A NO 20076475 A NO20076475 A NO 20076475A NO 20076475 L NO20076475 L NO 20076475L
- Authority
- NO
- Norway
- Prior art keywords
- nanobodies
- polypeptides
- willebrand factor
- antibodies against
- single domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Surgery (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Sammendrag Foreliggende oppfinnelse angår forbedrede Nanobodies(tm) mot von Willebrand Faktor (vWF), så vel som to polypeptider omfattende eller hovedsakelig bestående av en eller flere av slike Nanobodies. Foreliggende oppfinnelse angår også nukleinsyrer som koder for slike Nanobodies og polypeptider; fremgangsmåter for fremstilling av slike Nanobodies og polypeptider; vertsceller som uttrykker eller i stand til å uttrykke slike Nanobodies eller polypeptider; sammensetninger omfattende slike Nanobodies, polypeptider, nukleinsyrer eller vertsceller; og anvendelser av slike Nanobodies, slik som polypeptider, slik som nukleinsyrer, slik som vertsceller eller slik som sammensetninger, spesielt for profylaktisk, terapeutiske eller diagnostiske formål, slik som profylaktiske, terapeutiske eller diagnostiske formål.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68347405P | 2005-05-20 | 2005-05-20 | |
PCT/EP2006/004773 WO2006122825A2 (en) | 2005-05-20 | 2006-05-19 | Single domain vhh antibodies against von willebrand factor |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20076475L true NO20076475L (no) | 2008-02-18 |
Family
ID=37431613
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20076475A NO20076475L (no) | 2005-05-20 | 2007-12-17 | Enkeltdomene VHH antilegemer mot Van Willebrand faktor |
NO20190279A NO345342B1 (no) | 2005-05-20 | 2019-02-27 | Enkeltdomene VHH antistoffer mot Van Willebrand faktor |
NO2021020C NO2021020I1 (no) | 2005-05-20 | 2021-05-20 | kaplasizumab |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20190279A NO345342B1 (no) | 2005-05-20 | 2019-02-27 | Enkeltdomene VHH antistoffer mot Van Willebrand faktor |
NO2021020C NO2021020I1 (no) | 2005-05-20 | 2021-05-20 | kaplasizumab |
Country Status (27)
Country | Link |
---|---|
US (3) | US7807162B2 (no) |
EP (4) | EP2444424B1 (no) |
JP (1) | JP4986997B2 (no) |
KR (1) | KR101414438B1 (no) |
CN (1) | CN101213214B (no) |
AU (1) | AU2006249090B2 (no) |
BR (1) | BRPI0609797B8 (no) |
CA (2) | CA2608873C (no) |
CY (2) | CY1122579T1 (no) |
DK (1) | DK2444424T3 (no) |
ES (2) | ES2694247T3 (no) |
FR (1) | FR19C1005I2 (no) |
HU (2) | HUE039846T2 (no) |
IL (2) | IL187168A (no) |
LT (2) | LT2444424T (no) |
LU (1) | LUC00099I2 (no) |
MX (1) | MX2007014564A (no) |
NL (1) | NL300966I2 (no) |
NO (3) | NO20076475L (no) |
NZ (1) | NZ563392A (no) |
PL (2) | PL2444424T3 (no) |
PT (2) | PT3415535T (no) |
RU (1) | RU2433139C2 (no) |
SI (1) | SI2444424T1 (no) |
TR (1) | TR201815552T4 (no) |
WO (1) | WO2006122825A2 (no) |
ZA (1) | ZA200709570B (no) |
Families Citing this family (215)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE512364T1 (de) | 2002-08-07 | 2011-06-15 | Ablynx Nv | Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
EP1587838B1 (en) | 2003-01-10 | 2015-04-15 | Ablynx N.V. | Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation |
PT2311874T (pt) | 2004-07-22 | 2017-08-25 | Univ Erasmus Med Ct Rotterdam | Moléculas de ligação |
WO2006074947A2 (en) * | 2005-01-14 | 2006-07-20 | Ablynx N.V. | METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS |
KR101414438B1 (ko) | 2005-05-20 | 2014-07-10 | 아블린쓰 엔.브이. | 폰 빌레브란트 인자에 대한 단일 도메인 vhh 항체 |
WO2008049881A2 (en) * | 2006-10-25 | 2008-05-02 | Umc Utrecht Holding Bv | Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases |
EP2081960B1 (en) * | 2006-10-27 | 2018-06-27 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
WO2008074840A2 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
EP2557090A3 (en) | 2006-12-19 | 2013-05-29 | Ablynx N.V. | Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
US20110118185A9 (en) * | 2007-02-21 | 2011-05-19 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
NZ581097A (en) * | 2007-05-24 | 2012-03-30 | Ablynx Nv | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
CA2691940C (en) | 2007-07-03 | 2018-03-06 | Joost Alexander Kolkman | Methods for providing improved immunoglobulin sequences |
BRPI0819656A2 (pt) | 2007-11-27 | 2015-06-23 | Ablynx Nv | Seqüências de aminoácidos contras citocinas heterodiméricas e/ou seus receptores e polipeptídeos compreendendo as mesmas |
US20110183861A1 (en) * | 2008-01-29 | 2011-07-28 | Ablynn N.V. | Methods to stabilize proteins and polypeptides |
EP2247616A2 (en) * | 2008-03-05 | 2010-11-10 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making and uses thereof |
JP2011518772A (ja) * | 2008-03-21 | 2011-06-30 | アブリンクス エン.ヴェー. | フォンウィルブランド因子特異的結合因子及びこれらに関する使用方法 |
EP2260058A2 (en) | 2008-04-07 | 2010-12-15 | Ablynx N.V. | Single variable domains against the notch pathways |
US8217140B2 (en) | 2008-04-17 | 2012-07-10 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
GB2461546B (en) * | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
US9034325B2 (en) | 2008-07-22 | 2015-05-19 | Ablynx N.V. | Amino acid sequences directed against multitarget scavenger receptors and polypeptides |
ES2701649T3 (es) * | 2009-01-14 | 2019-02-25 | Ablynx Nv | Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos |
EP2403873A1 (en) * | 2009-03-05 | 2012-01-11 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
GB0905023D0 (en) * | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
EP2982690B1 (en) | 2009-04-30 | 2021-01-27 | Ablynx N.V. | Method for the production of domain antibodies |
HUE051430T2 (hu) | 2009-07-10 | 2021-03-01 | Ablynx Nv | Eljárás variábilis domének elõállítására |
EP3438126B1 (en) | 2009-09-03 | 2020-08-19 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
US20110172398A1 (en) * | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
EP2506874A1 (en) | 2009-12-01 | 2012-10-10 | Ablynx N.V. | Von willebrand factor specific binding agents and uses thereof |
US8962807B2 (en) | 2009-12-14 | 2015-02-24 | Ablynx N.V. | Single variable domain antibodies against OX40L, constructs and therapeutic use |
WO2011083141A2 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Method for generation of immunoglobulin sequences by using lipoprotein particles |
EP2531523A1 (en) | 2010-02-05 | 2012-12-12 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
PL2533761T3 (pl) | 2010-02-11 | 2019-09-30 | Ablynx N.V. | Sposoby i kompozycje do wytwarzania aerozoli |
WO2011098518A2 (en) | 2010-02-11 | 2011-08-18 | Ablynx Nv | Delivery of immunoglobulin variable domains and constructs thereof |
CN102781962B (zh) | 2010-03-03 | 2014-12-10 | 阿布林克斯公司 | 双互补位A-β结合多肽 |
WO2011117423A1 (en) | 2010-03-26 | 2011-09-29 | Ablynx N.V. | Immunoglobulin single variable domains directed against cxcr7 |
US9101674B2 (en) | 2010-03-29 | 2015-08-11 | Vib Vzw | Targeting and in vivo imaging of tumor-associated macrophages |
US9556273B2 (en) | 2010-03-29 | 2017-01-31 | Vib Vzw | Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages |
CN102906118B (zh) | 2010-05-20 | 2017-07-28 | 埃博灵克斯股份有限公司 | 与her3相关的生物材料 |
WO2011161263A1 (en) | 2010-06-25 | 2011-12-29 | Ablynx Nv | Pharmaceutical compositions for cutaneous administration |
WO2012175741A2 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
WO2012056000A1 (en) | 2010-10-29 | 2012-05-03 | Ablynx Nv | Method for the production of immunoglobulin single variable domains |
WO2012062713A1 (en) | 2010-11-08 | 2012-05-18 | Novartis Ag | Cxcr2 binding polypeptides |
US20150158948A9 (en) | 2011-03-28 | 2015-06-11 | Francis Descamps | Bispecific anti-cxcr7 immunoglobulin single variable domains |
PT2691415T (pt) | 2011-03-28 | 2018-10-19 | Ablynx Nv | Método para produção de formulações sólidas compreendendo domínios variáveis únicos de imunoglobulina |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
EP2707382B1 (en) | 2011-05-09 | 2019-07-17 | Ablynx NV | Method for the production of immunoglobulin single variable domains |
RU2661677C2 (ru) | 2011-05-27 | 2018-07-18 | Аблинкс Нв | Ингибирование резорбции кости с помощью связывающих rank-l пептидов |
EP4350345A2 (en) | 2011-06-23 | 2024-04-10 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
SI2723769T2 (sl) | 2011-06-23 | 2022-09-30 | Ablynx Nv | Tehnike za napovedovanje, zaznavanje in zmanjševanje nespecifične motnje proteina v testih, ki vključujejo domene imunoglobulina z eno spremenljivko |
CN104271598A (zh) | 2011-06-23 | 2015-01-07 | 埃博灵克斯股份有限公司 | 针对IgE的免疫球蛋白单可变结构域 |
CN108178800B (zh) * | 2011-08-17 | 2022-06-17 | 葛兰素集团有限公司 | 具有降低的与抗药物抗体结合的经修饰的单可变结构域抗体 |
EP2753644A1 (en) | 2011-09-09 | 2014-07-16 | Universiteit Utrecht Holding B.V. | Broadly neutralizing vhh against hiv-1 |
EP3311837A1 (en) | 2011-09-23 | 2018-04-25 | Ablynx NV | Prolonged inhibition of interleukin-6 mediated signaling |
DE102011121237A1 (de) | 2011-12-14 | 2013-06-20 | Universitätsklinikum Hamburg-Eppendorf | Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa |
DE102011121238A1 (de) | 2011-12-14 | 2013-06-20 | Universitätsklinikum Hamburg-Eppendorf | Einzeldomänen-antikörper gegen clostridium difficile toxine |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
JP6411333B2 (ja) | 2012-05-24 | 2018-10-24 | ブイアイビー ブイゼットダブリュVib Vzw | 腫瘍関連マクロファージのターゲティングおよびinvivoイメージング用抗マクロファージマンノース受容体単一可変ドメイン |
MX362394B (es) * | 2012-06-08 | 2019-01-15 | Glenmark Pharmaceuticals Sa | Anticuerpos anti-trka humanizados con sustituciones de aminoacidos. |
WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
JP6443344B2 (ja) | 2013-01-30 | 2018-12-26 | フエー・イー・ベー・フエー・ゼツト・ウエー | スクリーニングおよび薬物開発のための新規キメラポリペプチド |
PT2953973T (pt) | 2013-02-05 | 2019-10-25 | Univ Brussel Vrije | Agentes de ligação do receptor muscarínico de acetilololina e usos |
CA2906259C (en) | 2013-03-15 | 2022-12-06 | Vib Vzw | Anti-mmr single variable domains for prognosis and monitoring of cardiovascular diseases |
US10993420B2 (en) | 2013-03-15 | 2021-05-04 | Erasmus University Medical Center | Production of heavy chain only antibodies in transgenic mammals |
NL1040254C2 (en) * | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
EP3003372B1 (en) | 2013-06-07 | 2019-10-09 | Duke University | Inhibitors of complement factor h |
WO2014201400A2 (en) * | 2013-06-13 | 2014-12-18 | Biogen Idec Ma Inc. | Anti-factor viii antibodies or uses thereof |
AU2015217846B2 (en) | 2014-01-30 | 2019-10-10 | The Board Of Trustees Of The Leland Stanford Junior University | Opioid receptor binding agents and uses thereof |
WO2015158851A1 (en) * | 2014-04-16 | 2015-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the prevention or the treatment of bleeding episodes |
JP7325928B2 (ja) | 2014-05-16 | 2023-08-15 | アブリンクス エン.ヴェー. | 改善された免疫グロブリン可変ドメイン |
EP3143403B1 (en) | 2014-05-16 | 2021-10-27 | Ablynx N.V. | Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies |
NL2013007B1 (en) * | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
DK3194976T3 (da) | 2014-07-22 | 2020-07-13 | Vib Vzw | Fremgangsmåder til udvælgelse af midler, som stabiliserer proteinkomplekser |
WO2016057398A1 (en) | 2014-10-07 | 2016-04-14 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
MA41097A (fr) * | 2014-12-05 | 2017-10-10 | Glenmark Pharmaceuticals Sa | Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses |
WO2016097313A1 (en) | 2014-12-19 | 2016-06-23 | Ablynx N.V. | Cysteine linked nanobody dimers |
US10273305B2 (en) | 2015-04-02 | 2019-04-30 | Ablynx N.V. | Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity |
CA2981543A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
CN114920848A (zh) | 2015-05-13 | 2022-08-19 | 埃博灵克斯股份有限公司 | 基于cd3反应性的t细胞募集多肽 |
HUE045437T2 (hu) | 2015-05-13 | 2019-12-30 | Ablynx Nv | TCR-alfa-béta reaktivitásán alapulva T-sejtet toborzó polipeptidek |
WO2016186994A1 (en) * | 2015-05-15 | 2016-11-24 | Children's Medical Center Corporation | Methods relating to the diagnosis and treatment of thrombotic microangiopathy |
EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
EP3316885B1 (en) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
EP3329018B1 (en) | 2015-07-31 | 2021-03-31 | Medimmune Limited | Il-6 antagonists for use in treating hepcidin-mediated disorders |
NO2768984T3 (no) | 2015-11-12 | 2018-06-09 | ||
PL3374392T3 (pl) | 2015-11-13 | 2022-03-28 | Ablynx Nv | Ulepszone domeny zmienne immunoglobuliny wiążące albuminę surowicy |
AU2016355569B2 (en) * | 2015-11-18 | 2020-01-02 | Merck Sharp & Dohme Llc | CTLA4 binders |
CA3005488A1 (en) | 2015-11-18 | 2017-05-26 | Ablynx Nv | Improved serum albumin binders |
AU2016355568A1 (en) * | 2015-11-18 | 2018-06-21 | Merck Sharp & Dohme Llc | PD1/CTLA4 Binders |
SG11201803976VA (en) | 2015-11-27 | 2018-06-28 | Ablynx Nv | Polypeptides inhibiting cd40l |
US10626186B2 (en) * | 2016-01-26 | 2020-04-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-VWF D'D3 single-domain antibodies and methods of use |
CN109311968A (zh) | 2016-05-02 | 2019-02-05 | 埃博灵克斯股份有限公司 | 治疗rsv感染 |
RU2018138703A (ru) * | 2016-05-13 | 2020-06-15 | МЕДИММЬЮН, ЭлЭлСи | Слитые полипептиды cd40l-fc и способы их применения |
JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス,インク. | 単一ドメイン血清アルブミン結合タンパク質 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
KR102365977B1 (ko) | 2016-05-20 | 2022-02-22 | 하푼 테라퓨틱스, 인크. | 단일 쇄 가변 단편 cd3 결합 단백질 |
SG11201811280QA (en) | 2016-06-23 | 2019-01-30 | Ablynx Nv | Improved pharmacokinetic assays for immunoglobulin single variable domains |
WO2018007442A1 (en) | 2016-07-06 | 2018-01-11 | Ablynx N.V. | Treatment of il-6r related diseases |
WO2018029182A1 (en) | 2016-08-08 | 2018-02-15 | Ablynx N.V. | Il-6r single variable domain antibodies for treatment of il-6r related diseases |
US11098113B2 (en) | 2016-09-15 | 2021-08-24 | Vib Vzw | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
WO2018091606A1 (en) | 2016-11-16 | 2018-05-24 | Ablynx Nv | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
EP3544997A4 (en) | 2016-11-23 | 2020-07-01 | Harpoon Therapeutics, Inc. | PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN |
BR112019010602A2 (pt) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | proteínas trispecíficas para psma e métodos de uso |
WO2018099968A1 (en) | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Treatment of infection by respiratory syncytial virus (rsv) |
CN110049997B (zh) | 2016-12-07 | 2023-09-22 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合免疫球蛋白单可变结构域 |
BR112019014600A2 (pt) | 2017-01-17 | 2020-02-18 | Ablynx N.V. | Ligantes de albumina sérica melhorados |
US11414481B2 (en) | 2017-01-17 | 2022-08-16 | Ablynx N.V. | Serum albumin binders |
EP3576790A4 (en) | 2017-02-01 | 2020-12-23 | Yale University | TREATMENT OF DIURETIC RESISTANCE |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
EP3589725A1 (en) | 2017-02-28 | 2020-01-08 | Vib Vzw | Means and methods for oral protein delivery |
CA3056727A1 (en) | 2017-03-31 | 2018-10-04 | Ablynx N.V. | Improved immunogenicity assays |
US10865238B1 (en) * | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
KR20200005635A (ko) | 2017-05-11 | 2020-01-15 | 브이아이비 브이지더블유 | 가변 면역글로불린 도메인의 글리코실화 |
EP3621648A4 (en) | 2017-05-12 | 2021-01-20 | Harpoon Therapeutics, Inc. | TRISPECIFIC PROTEINS MSLN AND METHOD OF USE |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
JP7249961B2 (ja) | 2017-06-02 | 2023-03-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Adamts5、mmp13およびアグリカンに結合するポリペプチド |
BR112019025097A2 (pt) | 2017-06-02 | 2020-07-28 | Merck Patent Gmbh | imunoglobulinas de ligação a mmp13 |
EP3630847A1 (en) | 2017-06-02 | 2020-04-08 | Merck Patent GmbH | Adamts binding immunoglobulins |
KR20200013247A (ko) | 2017-06-02 | 2020-02-06 | 아블린쓰 엔.브이. | 아그레칸 결합 면역글로불린 |
WO2019016237A1 (en) | 2017-07-19 | 2019-01-24 | Vib Vzw | AGENTS FOR CONNECTING TO SERUM ALBUMIN |
AU2018346955A1 (en) | 2017-10-13 | 2020-04-30 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
CN111630070A (zh) | 2017-10-13 | 2020-09-04 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
WO2019086548A1 (en) | 2017-10-31 | 2019-05-09 | Vib Vzw | Novel antigen-binding chimeric proteins and methods and uses thereof |
US20200199206A1 (en) * | 2017-12-08 | 2020-06-25 | AC Thera, LLC | Bacterial toxin-neutralizing nanobodies and methods of making and using the same |
CA3087699A1 (en) | 2018-01-05 | 2019-07-11 | Corvidia Therapeutics, Inc. | Methods for treating il-6 mediated inflammation without immunosuppression |
US20210032316A1 (en) | 2018-02-05 | 2021-02-04 | Stichting Vu | Inverse Agonistic Anti-US28 Antibodies |
EP3749696A1 (en) | 2018-02-06 | 2020-12-16 | Ablynx N.V. | Methods of treating initial episode of ttp with immunoglobulin single variable domains |
WO2019155041A1 (en) | 2018-02-12 | 2019-08-15 | Vib Vzw | Gβγ COMPLEX ANTIBODIES AND USES THEREOF |
WO2019156566A1 (en) | 2018-02-12 | 2019-08-15 | Umc Utrecht Holding B.V. | Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain |
AR114269A1 (es) | 2018-02-26 | 2020-08-12 | Ablynx Nv | Secuencias nucleotídicas mejoradas que codifican para péptidos de unión |
CA3092421A1 (en) | 2018-03-01 | 2019-09-06 | Vrije Universiteit Brussel | Human pd-l1-binding immunoglobulins |
MX2020010091A (es) | 2018-03-27 | 2021-01-15 | Umc Utrecht Holding Bv | Trombolisis direccionada para tratamiento de trombosis microvascular. |
WO2019226050A2 (en) | 2018-05-24 | 2019-11-28 | Wageningen Universiteit | Novel viral anti-infective reagents |
KR102101561B1 (ko) * | 2018-07-25 | 2020-04-20 | 가톨릭대학교 산학협력단 | 신생혈관 표적용 조영제 조성물 및 이의 제조방법 |
JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | Dll3結合タンパク質および使用方法 |
EP3636657A1 (en) | 2018-10-08 | 2020-04-15 | Ablynx N.V. | Chromatography-free antibody purification method |
WO2020080941A1 (en) | 2018-10-16 | 2020-04-23 | Umc Utrecht Holding B.V. | Anti- low-density lipoprotein receptor-related protein 5/6 antibodies |
WO2020130838A2 (en) | 2018-12-21 | 2020-06-25 | Qvq Holding B.V. | Antibodies for preventing or treating candidiasis |
GB201901608D0 (en) | 2019-02-06 | 2019-03-27 | Vib Vzw | Vaccine adjuvant conjugates |
US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
JP2022529139A (ja) | 2019-04-02 | 2022-06-17 | イミュネチューン・ベー・フェー | 免疫刺激組成物及びその使用 |
CA3138028A1 (en) | 2019-04-29 | 2020-11-05 | Confo Therapeutics N.V. | Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs |
US20220289837A1 (en) | 2019-04-30 | 2022-09-15 | Vib Vzw | Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents |
JP2022531331A (ja) | 2019-05-01 | 2022-07-06 | ノヴォ ノルディスク アー/エス | 抗il-6抗体製剤 |
US20220228116A1 (en) | 2019-05-28 | 2022-07-21 | Vib Vzw | Cd8+ t-cells lacking plexins and their application in cancer treatment |
EP3976650A1 (en) | 2019-05-28 | 2022-04-06 | Vib Vzw | Cancer treatment by targeting plexins in the immune compartment |
EP4010079A1 (en) | 2019-08-05 | 2022-06-15 | Stichting VU | Identification and elimination of hcmv-infected cells |
WO2021039574A1 (ja) * | 2019-08-23 | 2021-03-04 | 株式会社カネカ | O結合型糖鎖修飾が抑制された重鎖抗体 |
EP3799881A1 (en) | 2019-10-04 | 2021-04-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Single domain antibodies specifically binding globo - series glycans |
US20220380456A1 (en) | 2019-10-21 | 2022-12-01 | Vib Vzw | Nanodisc-specific antigen-binding chimeric proteins |
CA3160506A1 (en) | 2019-11-11 | 2021-05-20 | Ibi-Ag Innovative Bio Insecticides Ltd. | Insect control nanobodies and uses thereof |
EP4065603A1 (en) | 2019-11-27 | 2022-10-05 | Vib Vzw | Positive allosteric modulators of the calcium-sensing receptor |
GB201918279D0 (en) | 2019-12-12 | 2020-01-29 | Vib Vzw | Glycosylated single chain immunoglobulin domains |
EP4077372A1 (en) | 2019-12-20 | 2022-10-26 | Vib Vzw | Nanobody exchange chromatography |
WO2021140205A1 (en) | 2020-01-10 | 2021-07-15 | Confo Therapeutics N.V. | Methods for generating antibodies and antibody fragments and libraries comprising same |
WO2021156490A2 (en) | 2020-02-06 | 2021-08-12 | Vib Vzw | Corona virus binders |
JP2023527609A (ja) | 2020-02-21 | 2023-06-30 | ハープーン セラピューティクス,インク. | Flt3結合タンパク質および使用方法 |
WO2021170540A1 (en) | 2020-02-25 | 2021-09-02 | Vib Vzw | Leucine-rich repeat kinase 2 allosteric modulators |
EP4144758A4 (en) | 2020-04-22 | 2024-05-15 | Mabwell Shanghai Bioscience Co Ltd | SINGLE VARIABLE DOMAIN ANTIBODIES TARGETING AND DERIVED FROM HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1) |
WO2021229104A1 (en) | 2020-05-15 | 2021-11-18 | Université de Liège | Anti-cd38 single-domain antibodies in disease monitoring and treatment |
AU2021297551A1 (en) * | 2020-06-26 | 2023-01-19 | Monash University | Anti-VWF antibodies and uses thereof |
WO2022003156A1 (en) | 2020-07-02 | 2022-01-06 | Oncurious Nv | Ccr8 non-blocking binders |
AR122933A1 (es) | 2020-07-10 | 2022-10-19 | Novo Nordisk As | Métodos para tratar la enfermedad cardiovascular |
WO2022063957A1 (en) | 2020-09-24 | 2022-03-31 | Vib Vzw | Biomarker for anti-tumor therapy |
US20230364049A1 (en) | 2020-09-24 | 2023-11-16 | Vib Vzw | Combination of p2y6 inhibitors and immune checkpoint inhibitors |
US20220153854A1 (en) | 2020-09-25 | 2022-05-19 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l |
WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるltbrアゴニスト |
WO2022133116A1 (en) * | 2020-12-18 | 2022-06-23 | Bioardis, Llc | Mesothelin binding molecules and uses thereof |
WO2022133050A1 (en) * | 2020-12-18 | 2022-06-23 | Bioardis, Llc | Gpc3 binding molecules and uses thereof |
CA3205465A1 (en) * | 2020-12-18 | 2022-06-23 | Bioardis, Llc | Epcam binding molecules and uses thereof |
US20240052031A1 (en) * | 2020-12-18 | 2024-02-15 | Bioardis, Llc | Cea6 binding molecules and uses thereof |
TW202239763A (zh) | 2020-12-18 | 2022-10-16 | 比利時商艾伯霖克斯公司 | 包含靶向IL-6和TNF-α的免疫球蛋白單可變結構域的多肽 |
GB202020502D0 (en) | 2020-12-23 | 2021-02-03 | Vib Vzw | Antibody composistion for treatment of corona virus infection |
WO2022136693A1 (en) * | 2020-12-23 | 2022-06-30 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
CA3206124A1 (en) | 2020-12-24 | 2022-06-30 | Vib Vzw | Non-blocking human ccr8 binders |
WO2022136647A1 (en) | 2020-12-24 | 2022-06-30 | Oncurious Nv | Human ccr8 binders |
EP4267621A1 (en) | 2020-12-24 | 2023-11-01 | Vib Vzw | Murine cross-reactive human ccr8 binders |
EP4288095A1 (en) | 2021-02-05 | 2023-12-13 | Vib Vzw | Sarbecovirus binders |
CN117794566A (zh) | 2021-02-05 | 2024-03-29 | Vib研究所 | 沙贝病毒结合剂 |
CA3211257A1 (en) | 2021-02-17 | 2022-08-25 | Vib Vzw | Inhibition of slc4a4 in the treatment of cancer |
EP4294516A1 (en) | 2021-02-19 | 2023-12-27 | Vib Vzw | Cation-independent mannose-6-phosphate receptor binders |
WO2022199804A1 (en) | 2021-03-24 | 2022-09-29 | Vib Vzw | Nek6 inhibition to treat als and ftd |
WO2022216157A1 (en) | 2021-04-09 | 2022-10-13 | Stichting Radboud Universiteit | Off the shelf proximity biotinylation enzyme |
WO2022242892A1 (en) | 2021-05-17 | 2022-11-24 | Université de Liège | Anti-cd38 single-domain antibodies in disease monitoring and treatment |
WO2022258606A1 (en) | 2021-06-07 | 2022-12-15 | Gadeta B.V. | Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response |
WO2022268993A1 (en) | 2021-06-23 | 2022-12-29 | Vib Vzw | Means and methods for selection of specific binders |
CN117580865A (zh) | 2021-06-29 | 2024-02-20 | 山东先声生物制药有限公司 | Cd16抗体及其应用 |
WO2023288217A2 (en) * | 2021-07-12 | 2023-01-19 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Methods and sytems for nanobody humanization |
WO2023016828A2 (en) | 2021-07-30 | 2023-02-16 | Vib Vzw | Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation |
AU2022320667A1 (en) | 2021-07-30 | 2024-03-14 | Shandong Simcere Biopharmaceutical Co., Ltd. | Anti-pvrig/anti-tigit bispecific antibody and application |
WO2023014222A1 (en) | 2021-08-03 | 2023-02-09 | Wageningen Universiteit | Argonaute-based nucleic acid detection system |
TW202342508A (zh) | 2021-12-17 | 2023-11-01 | 比利時商艾伯霖克斯公司 | 包含靶向TCRαβ、CD33和CD123的免疫球蛋白單可變結構域的多肽 |
WO2023135198A1 (en) | 2022-01-12 | 2023-07-20 | Vib Vzw | Human ntcp binders for therapeutic use and liver-specific targeted delivery |
WO2023148397A1 (en) | 2022-02-07 | 2023-08-10 | Vib Vzw | Engineered stabilizing aglycosylated fc-regions |
WO2023198848A1 (en) | 2022-04-13 | 2023-10-19 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
WO2023222825A1 (en) | 2022-05-18 | 2023-11-23 | Vib Vzw | Sarbecovirus spike s2 subunit binders |
WO2023227594A1 (en) | 2022-05-24 | 2023-11-30 | Gadeta Bv | Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof |
WO2023237541A1 (en) | 2022-06-07 | 2023-12-14 | Gadeta B.V. | Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response |
WO2024003873A1 (en) | 2022-06-30 | 2024-01-04 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Single variable domain antibodies against tumor necrosis factor-alpha |
WO2024008755A1 (en) | 2022-07-04 | 2024-01-11 | Vib Vzw | Blood-cerebrospinal fluid barrier crossing antibodies |
US20240075068A1 (en) | 2022-07-15 | 2024-03-07 | Gadeta B.V. | Novel soluble gamma T-cell (or soluble delta T-cell) receptor chains (or soluble gammadelta T-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response |
US20240132624A1 (en) | 2022-07-27 | 2024-04-25 | Ablynx N.V. | Polypeptides binding to a specific epitope of the neonatal fc receptor |
WO2024068744A1 (en) | 2022-09-27 | 2024-04-04 | Vib Vzw | Antivirals against human parainfluenza virus |
WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
WO2024096735A1 (en) | 2022-10-31 | 2024-05-10 | Stichting Amsterdam UMC | Single domain anti-cd169 antibodies |
WO2024101989A1 (en) | 2022-11-08 | 2024-05-16 | Stichting Amsterdam UMC | Activation inducible antigen receptors for adoptive immunotherapy |
WO2024105091A1 (en) | 2022-11-15 | 2024-05-23 | Imec Vzw | Method and system for droplet manipulation |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
US5238919A (en) * | 1986-05-30 | 1993-08-24 | Scipps Clinic And Research Foundation | Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor |
ATE122238T1 (de) | 1987-06-10 | 1995-05-15 | Dana Farber Cancer Inst Inc | Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen. |
US5200510A (en) | 1987-06-16 | 1993-04-06 | Zymogenetics, Inc. | Method for purifying factor viii:c, von willebrand factor and complexes thereof |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US5770198A (en) * | 1988-05-18 | 1998-06-23 | The Research Foundation Of The State Of New York | Platelet-specific chimeric 7E3 immunoglobulin |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
GB8905400D0 (en) | 1989-03-09 | 1989-04-19 | Jonker Margreet | Medicaments |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ES2109362T3 (es) | 1991-06-21 | 1998-01-16 | Univ Cincinnati | Unas proteinas administrables oralmente y metodo para hacerlas. |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
DE69334095T2 (de) | 1992-07-17 | 2007-04-12 | Dana-Farber Cancer Institute, Boston | Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen |
DK1589107T3 (da) | 1992-08-21 | 2010-04-26 | Univ Bruxelles | Immonuglobuliner uden lette kæder |
WO1994013806A1 (en) | 1992-12-11 | 1994-06-23 | The Dow Chemical Company | Multivalent single chain antibodies |
EP0684814B1 (en) | 1993-02-22 | 1998-06-17 | Alza Corporation | Compositions for oral delivery of active agents |
ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
GB9311454D0 (en) | 1993-06-03 | 1993-07-21 | Agricultural & Food Res | Pharmaceutical compositions |
WO1994029469A2 (en) | 1993-06-07 | 1994-12-22 | Vical Incorporated | Plasmids suitable for gene therapy |
DK0702721T3 (da) | 1993-06-09 | 2001-05-21 | Unilever Nv | Fremgangsmåde til fremstilling af fusionsproteiner, der omfatter ScFv fragmenter, ved hjælp af en transformeret skimmelsvamp |
FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
US6091639A (en) | 1993-08-27 | 2000-07-18 | Kabushiki Kaisha Toshiba | Non-volatile semiconductor memory device and data programming method |
KR960705209A (ko) | 1993-09-10 | 1996-10-09 | 잭 엠. 그랜노위츠 | 녹색 형광 단백의 용도 |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
WO1995022618A1 (en) | 1994-02-22 | 1995-08-24 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
US5670132A (en) * | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
ATE236993T1 (de) | 1994-11-30 | 2003-04-15 | Ajinomoto Kk | Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper |
AU4964896A (en) | 1995-01-19 | 1996-08-07 | Research Foundation Of The State University Of New York, The | Genes encoding an insect calcium channel |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US5693492A (en) | 1995-05-05 | 1997-12-02 | Merck & Co., Inc. | DNA encoding glutamate gated chloride channels |
EP0833907A1 (en) | 1995-06-23 | 1998-04-08 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
ATE184613T1 (de) | 1995-09-22 | 1999-10-15 | Novo Nordisk As | Varianten des grünen fluoreszenzproteins, gfp |
JP2000508892A (ja) | 1996-04-04 | 2000-07-18 | ユニリーバー・ナームローゼ・ベンノートシャープ | 多価および多特異的抗原結合タンパク |
US6027881A (en) | 1996-05-08 | 2000-02-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence |
CA2258518C (en) | 1996-06-27 | 2011-11-22 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Recognition molecules interacting specifically with the active site or cleft of a target molecule |
US6124128A (en) | 1996-08-16 | 2000-09-26 | The Regents Of The University Of California | Long wavelength engineered fluorescent proteins |
WO1998021355A1 (en) | 1996-11-15 | 1998-05-22 | Life Technologies, Inc. | Mutants of green fluorescent protein |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
WO1999009055A2 (en) | 1997-08-18 | 1999-02-25 | Innogenetics N.V. | Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders |
WO1999023221A2 (en) | 1997-10-27 | 1999-05-14 | Unilever Plc | Multivalent antigen-binding proteins |
AU3596599A (en) | 1998-01-26 | 1999-08-09 | Unilever Plc | Method for producing antibody fragments |
KR20010034512A (ko) | 1998-02-19 | 2001-04-25 | 베렌슨, 론 | 림프구 활성화 조절을 위한 조성물 및 그 방법 |
ATE535154T1 (de) * | 1998-03-12 | 2011-12-15 | Vhsquared Ltd | Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben |
CZ121599A3 (cs) * | 1998-04-09 | 1999-10-13 | Aventis Pharma Deutschland Gmbh | Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu |
EP0967284A1 (en) | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiesterases |
CA2336929C (en) | 1998-07-06 | 2005-10-04 | Euroscreen S.A. | High-throughput screening diagnostic and/or dosage method of an agonist and/or an antagonist for a calcium-coupled receptor |
US6228360B1 (en) * | 1998-08-19 | 2001-05-08 | Ajinomoto Co., Inc. | Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody |
US6251393B1 (en) * | 1998-10-23 | 2001-06-26 | The Brigham And Women's Hospital, Inc. | Conformation-specific anti-von Willebrand Factor antibodies |
EP1002861A1 (en) | 1998-10-26 | 2000-05-24 | Unilever Plc | Antigen-binding proteins comprising a linker which confers restricted conformational flexibility |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
AU3041100A (en) | 1999-01-05 | 2000-07-24 | Unilever Plc | Binding of antibody fragments to solid supports |
ATE276359T1 (de) | 1999-01-19 | 2004-10-15 | Unilever Nv | Verfahren zur herstellung von antikörperfragmenten |
CA2361678A1 (en) | 1999-02-05 | 2000-08-10 | Rijksuniversiteit Leiden | Method of modulating metabolite biosynthesis in recombinant cells |
US6419934B1 (en) * | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | TNF modulators for treating neurological disorders associated with viral infection |
JP4726302B2 (ja) | 1999-03-15 | 2011-07-20 | ユニバーシティ オブ ブリティッシュ コロンビア | Abc1ポリペプチドおよびコレステロール水準を調節する方法と試薬 |
CA2370351A1 (en) | 1999-04-22 | 2000-11-02 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins |
AU777461B2 (en) | 1999-06-18 | 2004-10-14 | Gilead Palo Alto, Inc. | Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter protein ABC1 |
WO2001002853A2 (en) | 1999-07-05 | 2001-01-11 | K.U. Leuven Research & Development | DETECTION OF VON-WILLEBRANDFACTOR (vWF) ACTIVITY |
AU6322900A (en) | 1999-08-02 | 2001-02-19 | Keygene N.V. | Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method |
GB9922124D0 (en) | 1999-09-17 | 1999-11-17 | Pfizer Ltd | Phosphodiesterase enzymes |
US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
DE19955408A1 (de) | 1999-11-18 | 2001-05-23 | Bayer Ag | GABA-B-Rezeptoren |
AU1859201A (en) | 1999-11-29 | 2001-06-12 | Unilever Plc | Immobilisation of proteins |
PT1233987E (pt) | 1999-11-29 | 2009-12-28 | Bac Ip B V | Imobilização de moléculas de ligação ao antigénio de um domínio |
ES2324280T3 (es) | 2000-03-14 | 2009-08-04 | Unilever N.V. | Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos. |
CA2441903C (en) | 2000-05-26 | 2012-07-31 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
AU2001268855A1 (en) | 2000-05-26 | 2001-12-03 | National Research Council Of Canada | Single-domain antigen-binding antibody fragments derived from llama antibodies |
US6506901B2 (en) | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
US6741957B1 (en) | 2000-07-21 | 2004-05-25 | Daimlerchrysler Corporation | Analytical tire model for vehicle durability and ride comfort analysis |
JP2004529610A (ja) * | 2000-10-13 | 2004-09-30 | ユーエイビー リサーチ ファンデーション | ヒト抗上皮増殖因子受容体一本鎖抗体 |
EP1360207B1 (en) | 2000-12-13 | 2011-06-22 | Bac Ip B.V. | Protein arrays of camelid heavy-chain immunoglobulin variable domains |
GB0031448D0 (en) | 2000-12-22 | 2001-02-07 | Leuven K U Res & Dev | Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation |
US7054297B1 (en) | 2000-12-28 | 2006-05-30 | Cisco Technology, Inc. | Distribution of packets to high data rate communications devices using multicast protocols |
DE10105526B4 (de) | 2001-02-07 | 2004-12-23 | Robert Bosch Gmbh | Verfahren zur Herstellung einer Klappenanordnung |
JP2004538324A (ja) | 2001-08-03 | 2004-12-24 | メディカル リサーチ カウンシル | 細胞内抗体 |
JP4213586B2 (ja) | 2001-09-13 | 2009-01-21 | 株式会社抗体研究所 | ラクダ抗体ライブラリーの作製方法 |
JP2005289809A (ja) * | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
KR100599789B1 (ko) | 2001-12-03 | 2006-07-12 | 삼성에스디아이 주식회사 | 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법 |
WO2003050531A2 (en) | 2001-12-11 | 2003-06-19 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
JP4323317B2 (ja) | 2001-12-21 | 2009-09-02 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) | 可変領域配列のクローニング方法 |
EP1461085A2 (en) | 2002-01-03 | 2004-09-29 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Immunoconjugates useful for treatment of tumours |
EP1517921B1 (en) | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual specific ligands with increased serum half-life |
US20050136056A1 (en) * | 2002-07-29 | 2005-06-23 | Shunsuke Kageyama | Pharmaceutical composition for the treatment of thrombocytopenia |
ATE512364T1 (de) | 2002-08-07 | 2011-06-15 | Ablynx Nv | Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha |
US7004940B2 (en) | 2002-10-10 | 2006-02-28 | Ethicon, Inc. | Devices for performing thermal ablation having movable ultrasound transducers |
EP1565482B1 (en) | 2002-10-23 | 2014-04-30 | Ludwig Institute for Cancer Research Ltd. | A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same |
WO2004041862A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
EP2267032A3 (en) | 2002-11-08 | 2011-11-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
EP1587838B1 (en) * | 2003-01-10 | 2015-04-15 | Ablynx N.V. | Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation |
ES2315664T3 (es) * | 2003-06-30 | 2009-04-01 | Domantis Limited | Anticuerpos de dominio unico (dab) pegilados. |
ES2352697T3 (es) | 2003-11-07 | 2011-02-22 | Ablynx N.V. | Anticuerpos de dominio único de camelidae vhh dirigidos contra el receptor del factor de crecimiento epidérmico y usos de los mismos. |
US7180370B2 (en) | 2004-09-01 | 2007-02-20 | Micron Technology, Inc. | CMOS amplifiers with frequency compensating capacitors |
US7566701B2 (en) * | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
BRPI0518151A2 (pt) * | 2004-10-13 | 2009-06-16 | Ablynx Nv | polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo |
WO2006074947A2 (en) | 2005-01-14 | 2006-07-20 | Ablynx N.V. | METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS |
KR101414438B1 (ko) * | 2005-05-20 | 2014-07-10 | 아블린쓰 엔.브이. | 폰 빌레브란트 인자에 대한 단일 도메인 vhh 항체 |
WO2008049881A2 (en) | 2006-10-25 | 2008-05-02 | Umc Utrecht Holding Bv | Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases |
JP2011518772A (ja) * | 2008-03-21 | 2011-06-30 | アブリンクス エン.ヴェー. | フォンウィルブランド因子特異的結合因子及びこれらに関する使用方法 |
-
2006
- 2006-05-19 KR KR1020077029416A patent/KR101414438B1/ko active IP Right Grant
- 2006-05-19 CA CA2608873A patent/CA2608873C/en not_active Expired - Fee Related
- 2006-05-19 CN CN200680024012.1A patent/CN101213214B/zh active Active
- 2006-05-19 NZ NZ563392A patent/NZ563392A/en unknown
- 2006-05-19 DK DK12151893.0T patent/DK2444424T3/en active
- 2006-05-19 EP EP12151893.0A patent/EP2444424B1/en active Active
- 2006-05-19 HU HUE12151893A patent/HUE039846T2/hu unknown
- 2006-05-19 RU RU2007147381/10A patent/RU2433139C2/ru active
- 2006-05-19 AU AU2006249090A patent/AU2006249090B2/en active Active
- 2006-05-19 EP EP06776035A patent/EP2007814A2/en not_active Withdrawn
- 2006-05-19 EP EP17175833.7A patent/EP3243839A1/en not_active Withdrawn
- 2006-05-19 SI SI200632287T patent/SI2444424T1/sl unknown
- 2006-05-19 CA CA2960105A patent/CA2960105A1/en not_active Abandoned
- 2006-05-19 LT LTEP12151893.0T patent/LT2444424T/lt unknown
- 2006-05-19 EP EP18186517.1A patent/EP3415535B1/en active Active
- 2006-05-19 TR TR2018/15552T patent/TR201815552T4/tr unknown
- 2006-05-19 US US11/920,793 patent/US7807162B2/en active Active
- 2006-05-19 PL PL12151893T patent/PL2444424T3/pl unknown
- 2006-05-19 PL PL18186517T patent/PL3415535T3/pl unknown
- 2006-05-19 MX MX2007014564A patent/MX2007014564A/es active IP Right Grant
- 2006-05-19 JP JP2008511652A patent/JP4986997B2/ja active Active
- 2006-05-19 PT PT181865171T patent/PT3415535T/pt unknown
- 2006-05-19 PT PT12151893T patent/PT2444424T/pt unknown
- 2006-05-19 BR BRPI0609797A patent/BRPI0609797B8/pt active IP Right Grant
- 2006-05-19 ES ES12151893T patent/ES2694247T3/es active Active
- 2006-05-19 WO PCT/EP2006/004773 patent/WO2006122825A2/en active Application Filing
- 2006-05-19 ES ES18186517T patent/ES2852423T3/es active Active
-
2007
- 2007-11-05 IL IL187168A patent/IL187168A/en active IP Right Grant
- 2007-11-06 ZA ZA200709570A patent/ZA200709570B/xx unknown
- 2007-12-17 NO NO20076475A patent/NO20076475L/no not_active Application Discontinuation
-
2010
- 2010-06-24 US US12/822,729 patent/US8372398B2/en active Active
- 2010-10-11 IL IL208607A patent/IL208607A0/en unknown
-
2013
- 2013-01-04 US US13/734,129 patent/US20130136736A1/en not_active Abandoned
-
2018
- 2018-11-07 CY CY20181101166T patent/CY1122579T1/el unknown
-
2019
- 2019-02-06 LU LU00099C patent/LUC00099I2/fr unknown
- 2019-02-11 HU HUS1900005C patent/HUS1900005I1/hu unknown
- 2019-02-11 NL NL300966C patent/NL300966I2/nl unknown
- 2019-02-13 FR FR19C1005C patent/FR19C1005I2/fr active Active
- 2019-02-14 CY CY2019006C patent/CY2019006I2/el unknown
- 2019-02-20 LT LTPA2019504C patent/LTC2444424I2/lt unknown
- 2019-02-27 NO NO20190279A patent/NO345342B1/no active Protection Beyond IP Right Term
-
2021
- 2021-05-20 NO NO2021020C patent/NO2021020I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20076475L (no) | Enkeltdomene VHH antilegemer mot Van Willebrand faktor | |
CY1122672T1 (el) | Βελτιωμενα nanobodiestm εναντι του παραγοντα νεκρωσης ογκων αλφα | |
MX2012005527A (es) | Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas. | |
WO2008074867A3 (en) | Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use | |
CL2008000912A1 (es) | Proteina insecticida hibrida que comprende dos proteinas cry del bacillus thuringiensis (bt) diferentes; molecula de acido nucleico que comprende dicha proteina; casete de expresion, vector recombinante que comprenden el acido nucleico; celula transg | |
DE602007008360D1 (de) | Aviäre telomerase reverse transkriptase | |
CL2012000063A1 (es) | Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07). | |
WO2006082251A3 (de) | Neue hydrophobinfusionsproteine, deren herstellung und verwendung | |
WO2007102149A3 (en) | Hydrazido derivatives of hyaluronic acid | |
PE20090726A1 (es) | Anticuerpos anti-ige apoptoticos | |
WO2006131564A3 (de) | Neue cystein-verarmte hydrophobinfusionsproteine, deren herstellung und verwendung | |
ATE541283T1 (de) | Verfahren zum mischen von farben in einem display | |
CL2011003122A1 (es) | Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer. | |
MX350962B (es) | Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion. | |
WO2009011855A3 (en) | Selection of nucleic acid-based sensor domains within nucleic acid switch platform | |
NO20082240L (no) | GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser | |
WO2010066411A3 (en) | Polypeptides having cellobiohydrolase ii activity | |
WO2009115614A3 (en) | Von willebrand factor specific binders and methods of use therefor | |
NO20083497L (no) | Modulering av bendannelse | |
RU2013112918A (ru) | Способы и материалы для придания зубам внешней белизны | |
EP2392655A3 (en) | Coagulation factor VII polypeptides | |
WO2009050277A3 (en) | Edta resistant s100a12 complexes (erac) | |
WO2005024006A3 (en) | Coagulation factor vii polypeptides | |
WO2008005470A3 (en) | Polypeptides that bind membrane proteins | |
WO2008082439A3 (en) | Antigen specific nanoparticles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |